SLC5A2 and type 1 diabetes mellitus: Meta-analyses of the RCTs on T1D have revealed that SGLT2 inhibitors cause significant reductions in glycated hemoglobin (HbA1c) levels, glycemic variability [15,16,17], insulin dose, body weight, and systolic blood pressure (SBP), without increasing the risk of hypoglycemia [18,19,20].